HUP9901659A2 - Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására - Google Patents

Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására

Info

Publication number
HUP9901659A2
HUP9901659A2 HU9901659A HUP9901659A HUP9901659A2 HU P9901659 A2 HUP9901659 A2 HU P9901659A2 HU 9901659 A HU9901659 A HU 9901659A HU P9901659 A HUP9901659 A HU P9901659A HU P9901659 A2 HUP9901659 A2 HU P9901659A2
Authority
HU
Hungary
Prior art keywords
diseases
damage
treatment
cell system
flupirtin
Prior art date
Application number
HU9901659A
Other languages
English (en)
Inventor
Werner E.G. Müller
Gabriela Pergande
Original Assignee
Asta Medica Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag. filed Critical Asta Medica Ag.
Publication of HUP9901659A2 publication Critical patent/HUP9901659A2/hu
Publication of HUP9901659A3 publication Critical patent/HUP9901659A3/hu
Publication of HU225742B1 publication Critical patent/HU225742B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

A találmány tárgyát flűpirtin hatóanyag vagy annak gyógyszerészetilegfelhasználható sóinak alkalmazása képezi őlyan betegségek kezeléséreszőlgáló gyógyszerkészítmény előállítására, amelyek a hematőpőetikűssejtrendszer kárősításával kapcsőlatősak. ŕ
HU9901659A 1995-11-07 1996-10-23 Use of flupirtin for producing pharmaceutical compositions suitable for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system HU225742B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19541405A DE19541405A1 (de) 1995-11-07 1995-11-07 Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
PCT/DE1996/002009 WO1997017072A2 (de) 1995-11-07 1996-10-23 Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen

Publications (3)

Publication Number Publication Date
HUP9901659A2 true HUP9901659A2 (hu) 1999-09-28
HUP9901659A3 HUP9901659A3 (en) 2001-04-28
HU225742B1 HU225742B1 (en) 2007-07-30

Family

ID=7776799

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901659A HU225742B1 (en) 1995-11-07 1996-10-23 Use of flupirtin for producing pharmaceutical compositions suitable for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system

Country Status (27)

Country Link
US (2) US6034111A (hu)
EP (1) EP0859613B1 (hu)
JP (1) JPH11514652A (hu)
KR (1) KR100512673B1 (hu)
CN (1) CN1116037C (hu)
AT (1) ATE316789T1 (hu)
AU (1) AU711207B2 (hu)
BG (1) BG63149B1 (hu)
BR (1) BR9611588A (hu)
CA (1) CA2189705C (hu)
CZ (1) CZ298115B6 (hu)
DE (2) DE19541405A1 (hu)
DK (1) DK0859613T3 (hu)
ES (1) ES2257755T3 (hu)
HK (1) HK1016508A1 (hu)
HU (1) HU225742B1 (hu)
MX (1) MX9803610A (hu)
NO (1) NO315074B1 (hu)
NZ (1) NZ330414A (hu)
PL (1) PL186537B1 (hu)
PT (1) PT859613E (hu)
RU (1) RU2200555C2 (hu)
SK (1) SK284601B6 (hu)
TW (1) TW393317B (hu)
UA (1) UA51682C2 (hu)
WO (1) WO1997017072A2 (hu)
ZA (1) ZA968783B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19625582A1 (de) * 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102009023162B4 (de) * 2009-05-29 2011-07-07 Corden PharmaChem GmbH, 68305 Verfahren zur Herstellung von Flupirtin
EP2462253B1 (en) * 2009-08-07 2021-04-07 Swagelok Company Low temperature carburization under soft vacuum
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
MX2014010460A (es) * 2012-03-02 2014-10-13 Meda Pharma Gmbh & Co Kg Formulaciones farmaceuticas que contienen flupirtina.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN172468B (hu) * 1990-07-14 1993-08-14 Asta Medica Ag
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin

Also Published As

Publication number Publication date
RU2200555C2 (ru) 2003-03-20
NO981898D0 (no) 1998-04-27
ATE316789T1 (de) 2006-02-15
HU225742B1 (en) 2007-07-30
DK0859613T3 (da) 2006-06-06
BG63149B1 (bg) 2001-05-31
TW393317B (en) 2000-06-11
CN1116037C (zh) 2003-07-30
EP0859613A2 (de) 1998-08-26
NO315074B1 (no) 2003-07-07
DE59611327D1 (de) 2006-04-13
HK1016508A1 (en) 1999-11-05
WO1997017072A3 (de) 1997-07-24
EP0859613B1 (de) 2006-02-01
SK58698A3 (en) 1998-09-09
CA2189705C (en) 2005-08-09
AU711207B2 (en) 1999-10-07
BR9611588A (pt) 1999-04-06
PL326629A1 (en) 1998-10-12
CZ298115B6 (cs) 2007-06-27
ZA968783B (en) 1997-05-27
CA2189705A1 (en) 1997-05-08
CZ128398A3 (cs) 1998-09-16
ES2257755T3 (es) 2006-08-01
WO1997017072A2 (de) 1997-05-15
HUP9901659A3 (en) 2001-04-28
PL186537B1 (pl) 2004-01-30
BG102404A (en) 1998-12-30
US6034111A (en) 2000-03-07
CN1201391A (zh) 1998-12-09
PT859613E (pt) 2006-06-30
NZ330414A (en) 1999-10-28
SK284601B6 (sk) 2005-07-01
AU1716597A (en) 1997-05-29
MX9803610A (es) 1998-09-30
KR19990067366A (ko) 1999-08-16
KR100512673B1 (ko) 2005-12-09
DE19541405A1 (de) 1997-05-15
UA51682C2 (uk) 2002-12-16
JPH11514652A (ja) 1999-12-14
US6034112A (en) 2000-03-07
NO981898L (no) 1998-04-27

Similar Documents

Publication Publication Date Title
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
DE69620606D1 (de) Feste oral anzuwendende arzeneiform
ATE211907T1 (de) Osmotisches arzneimittelfreisetzungssystem
SE9504661D0 (sv) New compounds
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
HUP0203249A2 (hu) Dipiridamol és mopidamol alkalmazása fibrinfüggő mikrokeringési rendellenességek kezelésére és megelőzésére szolgáló gyógyszer készítésére
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
DK1383540T3 (da) Fremgangsmdåer og farmaceutiske sammensætninger til sårheling
HUP0003571A2 (hu) 6,9-Hídkötésű eritromicin-származékok
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
SE0102440D0 (sv) New compound
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
SE8901003L (sv) Snabbloesliga preparat
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
SE9504662D0 (sv) New compounds
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
HUP0000108A2 (hu) Angiotenzin II antagonisták alkalmazása szimptómás szívelégtelenség kezelésére alkalmas gyógyászati készítmény előállítására
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
PT1231908E (pt) Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia
IS6555A (is) Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: MEDA PHARMA GMBH & CO. KG, DE

Free format text: FORMER OWNER(S): ASTA MEDICA AG., DE; ASTA MEDICA HEALTH PRODUCTS GMBH & CO. KG, DE; VIATRIS GMBH & CO. KG, DE; VIATRIS GMBH & CO. KG, DE

MM4A Lapse of definitive patent protection due to non-payment of fees